Japan moves closer to approving BioCardia heart failure therapy

PMDA signals support for the regulatory submission of CardiAMP, a personalized cell therapy for patients with limited treatment options. Heart failure is often viewed through the lens of cardiology, but it is equally a longevity challenge. The condition, more often, is the result of accumulated damage – a heart attack years ago, decades of vascular […] The post Japan moves closer to approving BioCardia heart failure therapy appeared first on Longevity.Technology .

This story was reported by Longevity.Technology. EUROPES curates Europe's most relevant coverage — read the full report at the original source.